UAE Slashes Prices For Over 400 Generics

The United Arab Emirates health ministry is cutting the prices of more than 400 generic drugs by as much as 77% as it seeks to reduce rising healthcare costs.

Coins_Arrow_UAE
The UAE has cut generics prices by as much as 77% • Source: Shutterstock

In a move to make medicines available at the lowest price in the Gulf region and to reduce overall healthcare costs, the United Arab Emirates Ministry of Health and Prevention has announced it is cutting the prices of 410 generic drugs by as much as 77%.

Prices are being slashed for drugs used to treat a wide range of ailments, from cardiovascular disease and hypertension to...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Drug Pricing

GB-Policy&Regulation (Premium-1): Lead Exposure Is Still a Problem for Kids, and the Pandemic Has Made It Worse

 
• By 

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

Polpharma And MSN Labs Team Up On Distribution

 
• By 

Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.

FDA Approves Accord’s Higher Strength Herceptin Biosimilar

 
• By 

Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.

‘It’s Not Going To Be An Easy Market’ – Hikma Talks Strategy For US Biosimilars

 
• By 

During Hikma’s first-half results call, the company delved into details of its strategic goals for biosimilars, small-molecule generics, injectables, GLP-1s and more.

More from Policy & Regulation

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Policy&Regulation-Free: Article with different widgets

Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.